Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Teva 'Disappointed' In Court's Patent Decision
No Outburst Of Opportunity In Tourette's Syndrome (Seeking Alpha)
Related NVS
Short Interest In Conatus Pharmaceuticals Surges
The Fentanyl Abuse Epidemic
Mallinckrodt Rebounds After FTC Probe; Doubts Rival Will Get FDA Nod (Investor's Business Daily)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

View Comments and Join the Discussion!